Venaxis Inc was organized on July 24, 2000, as a Colorado corporation. In December 2012, the Company's name was changed to Venaxis, Inc., from AspenBio Pharma, Inc. The Company is engaged in development and commercialization of products that address unmet diagnostic and therapeutic needs. The Company's product candidate, APPY1, is designed to be a novel blood-based diagnostic test that, if successfully cleared to be marketed by the United States Food and Drug Administration (FDA), will aid, through the test's negative predictive value, in the evaluation of low risk patients initially suspected of having acute appendicitis, thereby helping address the difficult challenge of triaging possible acute appendicitis patients in the hospital emergency department or urgent care settings. The APPY1, is intended to be used by emergency department and urgent care physicians to aid them in the evaluation of possible appendicitis in children, adolescent and young adult patients (ages 2 - 20) that present with abdominal pain. The FDA has regulatory marketing authority in the United States over its APPY1 products. The Company operates under ISO9001-4385 standards for cGMP manufacturing of medical devices. The Company is subject to various environmental laws pertaining to the disposal of hazardous medical waste. It contracts for disposal of hazardous waste with a licensed disposal facility.